Retatrutide
Retatrutide is a triple agonist — it acts on GIP, GLP-1, and glucagon receptors — and is taken once a week. In phase 2 trials it produced the largest average weight reduction reported for an incretin drug, with the usual GLP-1-class digestive side effects during escalation.
Studied forWeight management · Liver fat reduction · Appetite control · Energy expenditure
- How it works
- Triple agonist (GLP-1 / GIP / glucagon)
- Status
- Phase 3
- Half-life
- ~6 days
What is Retatrutide? →Retatrutide dosage calculator →Compare Retatrutide →